Digital Commons @ University of Digital Commons @ University of South Florida South Florida

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a causative agent of the coronavirus disease (CoVID-19), is a part of the β -coronaviridae family. In comparison with two other members of this family of coronaviruses infecting humans (SARS-CoV and Middle East Respiratory Syndrome (MERS) CoV), SARS-CoV-2 showed the most severe effects on the entire Earth population causing world-wide CoVID-19 pandemic. SARS-CoV-2 contains five major protein classes, such as four structural proteins (Nucleocapsid (N), Membrane (M), Envelop (E), and Spike Glycoprotein (S)) and Replicase polyproteins (R), which are synthesized as two polyproteins (ORF1a and ORF1ab) that are subsequently processed into 12 nonstructural proteins by three viral proteases. All these proteins share high sequence similarity with their SARS-CoV counterparts. Due to the severity of the current situation, most of the SARS-CoV-2-related research is focused on finding therapeutic solutions and the analysis of comorbidities during infection. However, studies on the peculiarities of the amino acid sequences of viral protein classes and their structure space analysis throughout the evolutionary time-frame are limited. At the same time, due to their structural malleability, viral proteins can be directly or indirectly associated with the dysfunctionality of the host cell proteins, which may lead to comorbidities during the infection and at the post infection stage. To fill these gaps, we conducted the evolutionary sequence-structure analysis of the viral protein classes to evaluate the rate of their evolutionary malleability. We also looked at the intrinsic disorder propensities of these viral proteins and confirmed that although they typically do not have long intrinsically disordered regions (IDRs), all of them have at least some levels of intrinsic disorder. Furthermore, short IDRs found in viral proteins are extremely effective and prioritize the proteins for host cell interactions, which may lead to host cell dysfunction. Next, the associations of viral proteins with the host cell proteins were studied, and a list of diseases which are associated with such host cell proteins was developed. Other than the usual set of diseases, we have identified some maladies, which may happen after the recovery from the infections. Comparison of the expression rates of the host cell proteins during the diseases suggested the existence of two distinct classes. First class includes proteins, which are directly associated with certain sets of diseases, where they have shared similar activities. Second class is related to the cytokine storm-mediated pro-inflammation (already known for its role in acute respiratory distress syndrome, ARDS), and neuroinflammation may trigger some of the neurological malignancies and neurodegenerative and neuropsychiatric diseases. Finally, since the transmembrane serine protease 2 (TMPRSS2), which is one of the leading proteins associated with the viral uptake, is an androgen-mediated protein, our study suggested that males and postmenopausal females can be more

[1]  V. Uversky,et al.  Intrinsic disorder perspective of an interplay between the renin-angiotensin-aldosterone system and SARS-CoV-2 , 2020, Infection, Genetics and Evolution.

[2]  Christopher J. Oldfield,et al.  Understanding COVID-19 via comparative analysis of dark proteomes of SARS-CoV-2, human SARS and bat SARS-like coronaviruses , 2020, Cellular and Molecular Life Sciences.

[3]  Jonathan P. Davies,et al.  Comparative multiplexed interactomics of SARS-CoV-2 and homologous coronavirus non-structural proteins identifies unique and shared host-cell dependencies , 2020, bioRxiv.

[4]  L. Qiang,et al.  Involvement of Spike Protein, Furin, and ACE2 in SARS-CoV-2-Related Cardiovascular Complications , 2020, SN Comprehensive Clinical Medicine.

[5]  P. Hofman,et al.  Pulmonary pathology and COVID-19: lessons from autopsy. The experience of European Pulmonary Pathologists , 2020, Virchows Archiv.

[6]  G. Fonarow,et al.  COVID-19 Pandemic: Cardiovascular Complications and Future Implications , 2020, American Journal of Cardiovascular Drugs.

[7]  A. Tong,et al.  Potential of SARS-CoV-2 to Cause CNS Infection: Biologic Fundamental and Clinical Experience , 2020, Frontiers in Neurology.

[8]  F. Massari,et al.  The pivotal role of TMPRSS2 in coronavirus disease 2019 and prostate cancer , 2020, Future oncology.

[9]  S. Pascarella,et al.  Sars-CoV-2 Envelope and Membrane Proteins: Structural Differences Linked to Virus Characteristics? , 2020, BioMed research international.

[10]  Paolo Fusar-Poli,et al.  Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic , 2020, The Lancet Psychiatry.

[11]  Giuseppe Magro,et al.  SARS-CoV-2 and COVID-19: Is interleukin-6 (IL-6) the ‘culprit lesion’ of ARDS onset? What is there besides Tocilizumab? SGP130Fc , 2020, Cytokine: X.

[12]  F. Negro,et al.  SARS-CoV-2 and liver damage: a possible pathogenetic link. , 2020, Hepatobiliary surgery and nutrition.

[13]  Victor G. Puelles,et al.  Multiorgan and Renal Tropism of SARS-CoV-2 , 2020, The New England journal of medicine.

[14]  M. Rugge,et al.  Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532) , 2020, Annals of Oncology.

[15]  L. Delgado-Roche,et al.  Oxidative Stress as Key Player in Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Infection , 2020, Archives of Medical Research.

[16]  Tianyuan Wang,et al.  Cytokine storm intervention in the early stages of COVID-19 pneumonia , 2020, Cytokine & Growth Factor Reviews.

[17]  Chakrabarty Dibyajyoti Das Gopalakrishnan Bulusu Arijit Roy Broto Network-Based Analysis of Fatal Comorbidities of COVID-19 and Potential Therapeutics , 2020 .

[18]  V. Uversky,et al.  Intrinsically disordered proteins of viruses: Involvement in the mechanism of cell regulation and pathogenesis , 2020, Progress in Molecular Biology and Translational Science.

[19]  James A. Foster,et al.  Shell disorder analysis predicts greater resilience of the SARS-CoV-2 (COVID-19) outside the body and in body fluids , 2020, Microbial Pathogenesis.

[20]  E. Bechara,et al.  Structural analysis of SARS-CoV-2 and prediction of the human interactome , 2020, 2003.13655.

[21]  V. Jha,et al.  The Novel Coronavirus 2019 epidemic and kidneys , 2020, Kidney International.

[22]  Arthur S Slutsky,et al.  Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target , 2020, Intensive Care Medicine.

[23]  Lixia Chen,et al.  Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods , 2020, Acta Pharmaceutica Sinica B.

[24]  Ujjwal Maulik,et al.  Structural facets of POU2F1 in light of the functional annotations and sequence-structure patterns , 2020, Journal of biomolecular structure & dynamics.

[25]  Ruchong Chen,et al.  Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China , 2020, The Lancet Oncology.

[26]  E. Holmes,et al.  A new coronavirus associated with human respiratory disease in China , 2020, Nature.

[27]  Kai Zhao,et al.  A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.

[28]  A Keith Dunker,et al.  Rigidity of the Outer Shell Predicted by a Protein Intrinsic Disorder Model Sheds Light on the COVID-19 (Wuhan-2019-nCoV) Infectivity , 2020, Biomolecules.

[29]  V. Uversky,et al.  Evolutionary Analyses of Sequence and Structure Space Unravel the Structural Facets of SOD1 , 2019, Biomolecules.

[30]  Vladimir N. Uversky,et al.  Intrinsically Disordered Proteins and Their “Mysterious” (Meta)Physics , 2019, Front. Phys..

[31]  U. Maulik,et al.  Understanding the evolutionary trend of intrinsically structural disorders in cancer relevant proteins as probed by Shannon entropy scoring and structure network analysis , 2019, BMC Bioinformatics.

[32]  L. Itzhaki,et al.  Kinetic and thermodynamic effects of phosphorylation on p53 binding to MDM2 , 2019, Scientific Reports.

[33]  Johnson Wahengbam Luwang,et al.  Phosphomimetic Mutation Destabilizes the Central Core Domain of Human p53 , 2018, IUBMB life.

[34]  Zsuzsanna Dosztányi,et al.  IUPred2A: context-dependent prediction of protein disorder as a function of redox state and protein binding , 2018, Nucleic Acids Res..

[35]  Zhongming Zhao,et al.  Decoding critical long non-coding RNA in ovarian cancer epithelial-to-mesenchymal transition , 2017, Nature Communications.

[36]  Yongqi Huang,et al.  Deciphering the promiscuous interactions between intrinsically disordered transactivation domains and the KIX domain , 2017, Proteins.

[37]  K. Teilum,et al.  Behaviour of intrinsically disordered proteins in protein–protein complexes with an emphasis on fuzziness , 2017, Cellular and Molecular Life Sciences.

[38]  J. Clarke,et al.  Conserved Helix-Flanking Prolines Modulate Intrinsically Disordered Protein:Target Affinity by Altering the Lifetime of the Bound Complex , 2017, Biochemistry.

[39]  M. Hour,et al.  SARS coronavirus papain-like protease up-regulates the collagen expression through non-Samd TGF-β1 signaling , 2017, Virus Research.

[40]  Núria Queralt-Rosinach,et al.  DisGeNET: a comprehensive platform integrating information on human disease-associated genes and variants , 2016, Nucleic Acids Res..

[41]  Lei Wan,et al.  SARS coronavirus papain-like protease induces Egr-1-dependent up-regulation of TGF-β1 via ROS/p38 MAPK/STAT3 pathway , 2016, Scientific Reports.

[42]  Lukasz Kurgan,et al.  Disordered nucleiome: Abundance of intrinsic disorder in the DNA‐ and RNA‐binding proteins in 1121 species from Eukaryota, Bacteria and Archaea , 2016, Proteomics.

[43]  A. Velázquez‐Campoy,et al.  Structural and functional characterization of phosphomimetic mutants of cytochrome c at threonine 28 and serine 47. , 2016, Biochimica et biophysica acta.

[44]  J. Forman-Kay,et al.  Modulation of Intrinsically Disordered Protein Function by Post-translational Modifications , 2016, The Journal of Biological Chemistry.

[45]  G. Lozano,et al.  MDM2 Associates with Polycomb Repressor Complex 2 and Enhances Stemness-Promoting Chromatin Modifications Independent of p53. , 2016, Molecular cell.

[46]  Fiona C. Denison,et al.  Phosphomimetic mutation of a conserved serine residue in Arabidopsis thaliana 14-3-3ω suggests a regulatory role of phosphorylation in dimerization and target interactions. , 2015, Plant physiology and biochemistry : PPB.

[47]  Lukasz Kurgan,et al.  In various protein complexes, disordered protomers have large per‐residue surface areas and area of protein‐, DNA‐ and RNA‐binding interfaces , 2015, FEBS letters.

[48]  K. Rajagopalan,et al.  Phosphorylation-induced Conformational Ensemble Switching in an Intrinsically Disordered Cancer/Testis Antigen* , 2015, The Journal of Biological Chemistry.

[49]  Yang Zhang,et al.  The I-TASSER Suite: protein structure and function prediction , 2014, Nature Methods.

[50]  L. Kay,et al.  Folding of an intrinsically disordered protein by phosphorylation as a regulatory switch , 2014, Nature.

[51]  C. Dieterich,et al.  Disorder and residual helicity alter p53-Mdm2 binding affinity and signaling in cells. , 2014, Nature chemical biology.

[52]  P. Nelson,et al.  The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. , 2014, Cancer discovery.

[53]  D. Meek,et al.  Critical role for p53-serine 15 phosphorylation in stimulating transactivation at p53-responsive promoters , 2014, Nucleic acids research.

[54]  A Keith Dunker,et al.  Intrinsically disordered proteins and intrinsically disordered protein regions. , 2014, Annual review of biochemistry.

[55]  S. K. Maurya,et al.  Caerulomycin A Enhances Transforming Growth Factor-β (TGF-β)-Smad3 Protein Signaling by Suppressing Interferon-γ (IFN-γ)-Signal Transducer and Activator of Transcription 1 (STAT1) Protein Signaling to Expand Regulatory T Cells (Tregs)* , 2014, The Journal of Biological Chemistry.

[56]  Christopher J. Oldfield,et al.  Classification of Intrinsically Disordered Regions and Proteins , 2014, Chemical reviews.

[57]  Alexander Dömling,et al.  Transient protein states in designing inhibitors of the MDM2-p53 interaction. , 2013, Structure.

[58]  P. Pitha,et al.  p53 Tumor Suppressor Protein Stability and Transcriptional Activity Are Targeted by Kaposi's Sarcoma-Associated Herpesvirus-Encoded Viral Interferon Regulatory Factor 3 , 2013, Molecular and Cellular Biology.

[59]  François-Xavier Theillet,et al.  Site-specific NMR mapping and time-resolved monitoring of serine and threonine phosphorylation in reconstituted kinase reactions and mammalian cell extracts , 2013, Nature Protocols.

[60]  S. Knapp,et al.  Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPP. , 2013, Cancer cell.

[61]  V. Uversky A decade and a half of protein intrinsic disorder: Biology still waits for physics , 2013, Protein science : a publication of the Protein Society.

[62]  N. Ribeiro,et al.  Prohibitin Ligands in Cell Death and Survival: Mode of Action and Therapeutic Potential , 2013, Chemistry & Biology.

[63]  A. Dunker,et al.  Understanding Viral Transmission Behavior via Protein Intrinsic Disorder Prediction: Coronaviruses , 2012, Journal of pathogens.

[64]  W. Kamitani,et al.  Severe Acute Respiratory Syndrome Coronavirus nsp1 Facilitates Efficient Propagation in Cells through a Specific Translational Shutoff of Host mRNA , 2012, Journal of Virology.

[65]  Vladimir N Uversky,et al.  Intrinsically disordered proteins and novel strategies for drug discovery , 2012, Expert opinion on drug discovery.

[66]  Y. Zou,et al.  DNA-PK, ATM and ATR collaboratively regulate p53-RPA interaction to facilitate homologous recombination DNA repair , 2012, Oncogene.

[67]  I. Bahar,et al.  Sequence Evolution Correlates with Structural Dynamics , 2012, Molecular biology and evolution.

[68]  Carlo Camilloni,et al.  Determination of secondary structure populations in disordered states of proteins using nuclear magnetic resonance chemical shifts. , 2012, Biochemistry.

[69]  V. Uversky,et al.  SS-Stabilizing Proteins Rationally: Intrinsic Disorder-Based Design of Stabilizing Disulphide Bridges in GFP , 2012, Journal of biomolecular structure & dynamics.

[70]  Do-Hyoung Kim,et al.  Understanding pre-structured motifs (PreSMos) in intrinsically unfolded proteins. , 2012, Current protein & peptide science.

[71]  V. Uversky,et al.  Molecular mechanisms of the anomalous thermal aggregation of green fluorescent protein. , 2011, Biochimica et biophysica acta.

[72]  C. Sander,et al.  Direct-coupling analysis of residue coevolution captures native contacts across many protein families , 2011, Proceedings of the National Academy of Sciences.

[73]  Jiandong Chen,et al.  Regulation of MDM2 E3 Ligase Activity by Phosphorylation after DNA Damage , 2011, Molecular and Cellular Biology.

[74]  V. Uversky,et al.  Sequential melting of two hydrophobic clusters within the green fluorescent protein GFP-cycle3. , 2011, Biochemistry.

[75]  Peter E. Wright,et al.  Graded enhancement of p53 binding to CREB-binding protein (CBP) by multisite phosphorylation , 2010, Proceedings of the National Academy of Sciences.

[76]  B. Vojtesek,et al.  A Novel p53 Phosphorylation Site within the MDM2 Ubiquitination Signal , 2010, The Journal of Biological Chemistry.

[77]  M. Hüttemann,et al.  Phosphomimetic substitution of cytochrome C tyrosine 48 decreases respiration and binding to cardiolipin and abolishes ability to trigger downstream caspase activation. , 2010, Biochemistry.

[78]  Roland L. Dunbrack,et al.  PONDR-FIT: a meta-predictor of intrinsically disordered amino acids. , 2010, Biochimica et biophysica acta.

[79]  Chandra Verma,et al.  Differences in the transactivation domains of p53 family members: a computational study , 2010, BMC Genomics.

[80]  William Arbuthnot Sir Lane,et al.  ATM activates p53 by regulating MDM2 oligomerization and E3 processivity , 2009, The EMBO journal.

[81]  V. Uversky,et al.  Solution structure and dynamics of the chimeric SH3 domains, SHH- and SHA-"Bergeracs". , 2009, Biochimica et biophysica acta.

[82]  A Keith Dunker,et al.  Analysis of structured and intrinsically disordered regions of transmembrane proteins. , 2009, Molecular bioSystems.

[83]  T. Kamura,et al.  Degradation of Phosphorylated p53 by Viral Protein-ECS E3 Ligase Complex , 2009, PLoS pathogens.

[84]  Wei Gu,et al.  Modes of p53 Regulation , 2009, Cell.

[85]  H. Jane Dyson,et al.  Cooperative regulation of p53 by modulation of ternary complex formation with CBP/p300 and HDM2 , 2009, Proceedings of the National Academy of Sciences.

[86]  H. Dyson,et al.  Mapping the interactions of the p53 transactivation domain with the KIX domain of CBP. , 2009, Biochemistry.

[87]  A. Fersht,et al.  Regulation by phosphorylation of the relative affinities of the N-terminal transactivation domains of p53 for p300 domains and Mdm2 , 2009, Oncogene.

[88]  A. Wlodawer,et al.  Structural basis for p300 Taz2-p53 TAD1 binding and modulation by phosphorylation. , 2009, Structure.

[89]  V. Uversky,et al.  Function and structure of inherently disordered proteins. , 2008, Current opinion in structural biology.

[90]  T. Shono,et al.  Phosphorylation of Thr18 and Ser20 of p53 in Ad-p53-induced apoptosis. , 2008, Neuro-oncology.

[91]  A Keith Dunker,et al.  A computational investigation of allostery in the catabolite activator protein. , 2007, Journal of the American Chemical Society.

[92]  A. Fersht,et al.  Four domains of p300 each bind tightly to a sequence spanning both transactivation subdomains of p53 , 2007, Proceedings of the National Academy of Sciences.

[93]  S. Francoz,et al.  Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[94]  Geng-Hung Liu,et al.  Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[95]  S. Vishveshwara,et al.  A network representation of protein structures: implications for protein stability. , 2005, Biophysical journal.

[96]  P. Tompa,et al.  IUPred: web server for the prediction of intrinsically unstructured regions of proteins based on estimated energy content , 2005, Bioinform..

[97]  K. Harms,et al.  Structural basis for gene activation by p53 family members , 2005, Cancer biology & therapy.

[98]  Zoran Obradovic,et al.  Optimizing Long Intrinsic Disorder Predictors with Protein Evolutionary Information , 2005, J. Bioinform. Comput. Biol..

[99]  Ana Sevilla,et al.  p53 Stabilization and Accumulation Induced by Human Vaccinia-Related Kinase 1 , 2004, Molecular and Cellular Biology.

[100]  E. Appella,et al.  Phosphorylation Site Interdependence of Human p53 Post-translational Modifications in Response to Stress* , 2003, Journal of Biological Chemistry.

[101]  M. McCoy,et al.  Flexible lid to the p53-binding domain of human Mdm2: Implications for p53 regulation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[102]  A. Haas,et al.  MdmX Is a RING Finger Ubiquitin Ligase Capable of Synergistically Enhancing Mdm2 Ubiquitination* , 2002, The Journal of Biological Chemistry.

[103]  A. Fersht,et al.  Molecular mechanism of the interaction between MDM2 and p53. , 2002, Journal of molecular biology.

[104]  C. Prives,et al.  Efficient Specific DNA Binding by p53 Requires both Its Central and C-Terminal Domains as Revealed by Studies with High-Mobility Group 1 Protein , 2002, Molecular and Cellular Biology.

[105]  M E J Newman,et al.  Community structure in social and biological networks , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[106]  N. Little,et al.  Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms , 2001, EMBO reports.

[107]  V. Rotter,et al.  Integrity of the N‐terminal transcription domain of p53 is required for mutant p53 interference with drug‐induced apoptosis , 2001, The EMBO journal.

[108]  P. Chène Targeting p53 in cancer. , 2001, Current medicinal chemistry. Anti-cancer agents.

[109]  T. Hupp,et al.  Inhibition of p53‐dependent transcription by BOX‐I phospho‐peptide mimetics that bind to p300 , 2001, EMBO reports.

[110]  V. Rotter,et al.  Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. , 2000, Cancer research.

[111]  Yusuke Nakamura,et al.  p53AIP1, a Potential Mediator of p53-Dependent Apoptosis, and Its Regulation by Ser-46-Phosphorylated p53 , 2000, Cell.

[112]  J. Stock,et al.  Signal transduction: Response regulators on and off , 2000, Current Biology.

[113]  K. Sakaguchi,et al.  Damage-mediated Phosphorylation of Human p53 Threonine 18 through a Cascade Mediated by a Casein 1-like Kinase , 2000, The Journal of Biological Chemistry.

[114]  D. Meek,et al.  Protein kinase CK1 is a p53‐threonine 18 kinase which requires prior phosphorylation of serine 15 , 1999, FEBS letters.

[115]  M. Oren Regulation of the p53 Tumor Suppressor Protein* , 1999, The Journal of Biological Chemistry.

[116]  C S Raman,et al.  Isothermal titration calorimetry of protein-protein interactions. , 1999, Methods.

[117]  S. Vishveshwara,et al.  Identification of side-chain clusters in protein structures by a graph spectral method. , 1999, Journal of molecular biology.

[118]  Yolande F M Ramos,et al.  Comparative study of the p53-mdm2 and p53-MDMX interfaces , 1999, Oncogene.

[119]  D. Livingston,et al.  p300/MDM2 complexes participate in MDM2-mediated p53 degradation. , 1998, Molecular cell.

[120]  Ettore Appella,et al.  Phosphorylation of p53: a Novel Pathway for p53 Inactivation in Human T-Cell Lymphotropic Virus Type 1-Transformed Cells , 1998, Journal of Virology.

[121]  L. Johnson,et al.  Structural basis for control by phosphorylation. , 1997, Chemical reviews.

[122]  Yoichi Taya,et al.  DNA Damage-Induced Phosphorylation of p53 Alleviates Inhibition by MDM2 , 1997, Cell.

[123]  M. Oren,et al.  Mdm2 promotes the rapid degradation of p53 , 1997, Nature.

[124]  Stephen N. Jones,et al.  Regulation of p53 stability by Mdm2 , 1997, Nature.

[125]  A. Levine,et al.  Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain , 1996, Science.

[126]  A. Jochemsen,et al.  MDMX: a novel p53‐binding protein with some functional properties of MDM2. , 1996, The EMBO journal.

[127]  Bruce A. Johnson,et al.  NMR View: A computer program for the visualization and analysis of NMR data , 1994, Journal of biomolecular NMR.

[128]  D. Lane,et al.  What the papers say: The p53‐mdm2 autoregulatory feedback loop: A paradigm for the regulation of growth control by p53? , 1993 .

[129]  P. Meltzer,et al.  Amplification of a gene encoding a p53-associated protein in human sarcomas , 1992, Nature.

[130]  L. Donehower,et al.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.

[131]  R. Doolittle,et al.  A simple method for displaying the hydropathic character of a protein. , 1982, Journal of molecular biology.

[132]  G. Daughdrill,et al.  Using NMR Chemical Shifts to Determine Residue-Specific Secondary Structure Populations for Intrinsically Disordered Proteins. , 2018, Methods in enzymology.

[133]  K. Rajarathnam,et al.  Isothermal titration calorimetry of membrane proteins - progress and challenges. , 2014, Biochimica et biophysica acta.

[134]  Sonia Longhi,et al.  Structural disorder in viral proteins. , 2010, Protein and peptide letters.

[135]  E. Lewis,et al.  Isothermal titration calorimetry: experimental design, data analysis, and probing macromolecule/ligand binding and kinetic interactions. , 2008, Methods in cell biology.

[136]  C. Chuong,et al.  Article type Software , 2007 .

[137]  Bruce A Johnson,et al.  Using NMRView to visualize and analyze the NMR spectra of macromolecules. , 2004, Methods in molecular biology.

[138]  Wei Zhang,et al.  Mdm-2 binding and TAFII31 recruitment is regulated by hydrogen bond disruption between the p53 residues Thr18 and Asp21 , 2002, Oncogene.

[139]  V. Mikhail,et al.  MINI REVIEW P53: AN UBIQUITOUS TARGET OF ANTICANCER DRUGS , 2002 .

[140]  A Keith Dunker,et al.  Intrinsic disorder and protein function. , 2002, Biochemistry.

[141]  H. Dyson,et al.  Insights into the structure and dynamics of unfolded proteins from nuclear magnetic resonance. , 2002, Advances in protein chemistry.

[142]  P. Romero,et al.  Sequence complexity of disordered protein , 2001, Proteins.

[143]  M. Hollstein,et al.  p53 and human cancer: the first ten thousand mutations. , 2000, Advances in cancer research.

[144]  Wim G. J. Hol,et al.  The role of the α-helix dipole in protein function and structure , 1985 .

[145]  P. Radivojac,et al.  PROTEINS: Structure, Function, and Bioinformatics Suppl 7:176–182 (2005) Exploiting Heterogeneous Sequence Properties Improves Prediction of Protein Disorder , 2022 .

[146]  R. Sheridan,et al.  a-Helix dipole model and electrostatic stabilization of 4-a-helical proteins , 2022 .